可溶性ST2及其配体IL-33与疾病关系的研究进展*

doi:10.3969/j.issn.1671-2587.2021.01.033

临床输血与检验 ›› 2021, Vol. 23 ›› Issue (1): 131-134.DOI: 10.3969/j.issn.1671-2587.2021.01.033

• 综述 • 上一篇

可溶性ST2及其配体IL-33与疾病关系的研究进展^*

胡蝶, 浦春

241001 芜湖,皖南医学院弋矶山医院检验科

收稿日期:2020-08-20 发布日期:2021-02-22
通讯作者: 浦春,男,教授,硕士生导师,主要从事免疫学与分子生物学研究,（E-mail）philipcpu.163.com。
作者简介:胡蝶（1995-）,女,安徽淮南人,检验师,硕士,主要从事临床检验诊断学研究,（E-mail）214552487@qq.com。
基金资助:
*本课题受安徽省大学生创新创业训练计划项目（No.S201910368117）资助

Received:2020-08-20 Published:2021-02-22

摘要/Abstract

摘要： 可溶性生长刺激表达基因2蛋白（soluble growth stimulation expressed gene 2,sST2）是白细胞介素受体（interleukin receptor,IL-1R）家族中的一员,作为一种心力衰竭的标志物而被广泛研究。目前已知其参与心肌的重塑和保护,以及糖尿病并发症的发生发展等;其配体白介素-33（interleukin-33,IL-33）作为一种炎性细胞因子,在炎症性疾病、变态反应性疾病、代谢性疾病、肿瘤等疾病进程中发挥广泛作用。IL-33与sST2结合后参与体内的免疫反应,也与第2组固有淋巴样细胞（group 2 innate lymphoid cells,ILC2s）联合发挥作用。sST2/IL-33不仅有望成为临床诊断中重要的生物标志物,还可能成为相关疾病治疗的潜在靶点,本文就sST2及其配体IL-33与疾病关系的研究进展进行综述。

关键词: sST2, IL-33, 心力衰竭, 糖尿病

中图分类号:

R446

胡蝶, 浦春. 可溶性ST2及其配体IL-33与疾病关系的研究进展^*[J]. 临床输血与检验, 2021, 23(1): 131-134.

参考文献

[1] TOMINAGA S.A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor[J].FEBS Lett,1989,258(2):301-304.
[2] WEINBERG E O,SHIMPO M,DE KEULENAER G W,et al.Expression and regulation of ST2,an interleukin-1 receptor family member,in cardiomyocytes and myocardial infarction[J].Circulation,2002,106(23):2961-2966.
[3] KRIECHBAUM S D,WIEDENROTH C B,PETERS K,et al.Galectin-3,GDF-15,and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension[J].Biomarkers,2020,25(7):578-586.
[4] VIANELLO E,DOZIO E,TACCHINI L,et al.ST2/IL-33 signaling in cardiac fibrosis[J].Int J Biochem Cell Biol,2019,116:105619.
[5] LIEW F Y,GIRARD J P,TURNQUIST H R.Interleukin-33 in health and disease[J].Nat Rev Immunol,2016,16(11):676-689.
[6] GABRYELSKA A,KUNA P,ANTCZAK A,et al.IL-33 mediated inflammation in chronic respiratory diseases-understanding the role of the member of IL-1 superfamily[J].Front Immunol,2019,10:692.
[7] MILLER A M,LIEW F Y.The IL-33/ST2 pathway-A new therapeutic target in cardiovascular disease[J].Pharmacol Ther,2011,131(2):179-186.
[8] ELSHERBINY N M,SAID E,ATEF H,et al.Renoprotective effect of calycosin in high fat diet-fed/STZ injected rats:Effect on IL-33/ST2 signaling,oxidative stress and fibrosis suppression[J].Chem Biol Interact,2020,315:108897.
[9] MAGER L F,RIETHER C,SCHÜRCH C M,et al.IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms[J].J Clin Invest,2015,125(7):2579-2591.
[10] WANG Y Q,LUO H M,WEI M Y,et al.IL-33/IL1RL1 axis regulates cell survival through the p38 MAPK pathway in acute myeloid leukemia[J].Leuk Res,2020,96:106409.
[11] ALEKSOVA A,PALDINO A,BELTRAMI A P,et al.Cardiac biomarkers in the emergency department:the role of soluble ST2 (sST2) in acute heart failure and acute coronary syndrome-there is meat on the bone[J].J Clin Med,2019,8(2):E270.
[12] DOLAPOGLU A,AVCI E,YILDIRIM T,et al.Using soluble ST2 to predict adverse postoperative outcomes in patients with impaired left ventricular function undergoing coronary bypass surgery[J].Medicina (Kaunas),2019,55(9):E572.
[13] AULA H,SKYTTÄ T,TUOHINEN S,et al.ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer[J].Breast,2020,49:183-186.
[14] FUDIM M,KELLY J P,JONES A D,et al.Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?[J].Am Heart J,2020,220:97-107.
[15] TYMIŃSKA A,KAPŁON-CIEŚLICKA A,OZIERAŃSKI K,et al.Association of galectin-3 and soluble ST2,and their changes,with echocardiographic parameters and development of heart failure after ST-segment elevation myocardial infarction[J].Dis Markers,2019,2019:9529053.
[16] 韩蕊,左霞,许丽明.血清可溶性ST2对老年急性心力衰竭患者病情程度及预后的评估价值[J].中华保健医学杂志,2019,21(5):470-472.
[17] 杨萍,刘培晶,丁澍,等.hs-cTnT、sST2联合BNP评估射血分数降低的慢性心力衰竭的临床意义[J].江苏大学学报(医学版),2019,29(5):414-418.
[18] CANER S,USLUOĞULLARI C A,BALKAN F,et al.Is IL-33 useful to detect early stage of renal failure?[J].Ren Fail,2014,36(1):78-80.
[19] BEREZIN A E.Cardiovascular biomarkers in routine screening of diabetic patients[J]. Clin Med Biochemistry Open Access, 2015, 1(107): 2471-2663.
[20] FOUSTERIS E,MELIDONIS A,PANOUTSOPOULOS G,et al.Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes,especially when accompanied with left ventricular diastolic dysfunction[J].Cardiovasc Diabetol,2011,10:101.
[21] BAO Y S,NA S P,ZHANG P,et al.Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease[J].J Clin Immunol,2012,32(3):587-594.
[22] ALAM M L,KATZ R,BELLOVICH K A,et al.Soluble ST2 and galectin-3 and progression of CKD[J].Kidney Int Rep,2019,4(1):103-111.
[23] HOMSAK E,EKART R.ST2 as a novel prognostic marker in end-stage renal disease patients on hemodiafiltration[J].Clin Chim Acta,2018,477:105-112.
[24] WANG S,WEI F,CHEN H Y,et al.The prognostic value of soluble ST2 in maintenance hemodialysis patients:a meta-analysis[J].Blood Purif,2020,49(1/2):114-120.
[25] GUNGOR O,UNAL H U,GUCLU A,et al.IL-33 and ST2 levels in chronic kidney disease:Associations with inflammation,vascular abnormalities,cardiovascular events,and survival[J].PLoS One,2017,12(6):e0178939.DOI:10.1371/journal.pone.0178939.
[26] NAKAJIMA S,ISHIMARU K,KOBAYASHI A,et al.Resveratrol inhibits IL-33-mediated mast cell activation by targeting the MK2/3-PI3K/Akt axis[J].Sci Rep,2019,9(1):18423.
[27] PENG Y Q,QIN Z L,FANG S B,et al.Effects of myeloid and plasmacytoid dendritic cells on ILC2s in patients with allergic rhinitis[J].J Allergy Clin Immunol,2020,145(3):855-867.e8.
[28] CAI H,WANG J,MO Y Q,et al.Salidroside suppresses group 2 innate lymphoid cell-mediated allergic airway inflammation by targeting IL-33/ST2 axis[J].Int Immunopharmacol,2020,81:106243.
[29] BAI F H,BA F Y,YOU Y J,et al.Decreased ST2 expression is associated with gastric cancer progression and pathogenesis[J].Oncol Lett,2019,17(6):5761-5767.
[30] EISSMANN M F,DIJKSTRA C,JARNICKI A,et al.IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization[J].Nat Commun,2019,10(1):2735.
[31] QI L,ZHANG Q Y,MIAO Y H,et al.Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development[J].Int J Cancer,2020,146(5):1421-1434.
[32] LI A,HERBST R H,CANNER D,et al.IL-33 signaling alters regulatory T cell diversity in support of tumor development[J].Cell Rep,2019,29(10):2998-3008.e8.
[33] HATZIOANNOU A,BANOS A,SAKELAROPOULOS T,et al.An intrinsic role of IL-33 in Treg cell-mediated tumor immunoevasion[J].Nat Immunol,2020,21(1):75-85.

可溶性ST2及其配体IL-33与疾病关系的研究进展^*

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	马洁, 孙明, 钱广兵. 同型半胱氨酸对急性心力衰竭患者预后的相关性分析[J]. 临床输血与检验, 2020, 22(4): 440-443.
[2]	鲍家军, 蒋艺兰, 汤小峰, 李建平. 甘精胰岛素联合格列美脲对2型糖尿病老年患者血糖控制及SPARC蛋白表达的影响^*[J]. 临床输血与检验, 2019, 21(6): 568-570.
[3]	赵俐丽, 叶山东. 1型糖尿病住院患者血尿酸与糖尿病肾脏疾病的关系*[J]. 临床输血与检验, 2019, 21(3): 273-276.
[4]	朱合, 张勇燕, 吴书笔. 脂蛋白相关磷脂酶A2在妊娠期糖尿病中的应用价值[J]. 临床输血与检验, 2019, 21(3): 318-319.
[5]	罗立, 冯锦红, 孔刘莎, 王迪生. β-catenin和cadherin蛋白联合血尿酸检测对DN预后的评估[J]. 临床输血与检验, 2019, 21(2): 180-183.
[6]	农贤刚, 程卫萍. 血清GDF-15和sCD163与2型糖尿病肾病的相关性[J]. 临床输血与检验, 2018, 20(5): 539-542.
[7]	郭喜, 廖远泉, 沈继龙. 糖化血红蛋白实验室检测技术及方法学进展[J]. 临床输血与检验, 2017, 19(6): 646-650.
[8]	韩静, 苏胜偶, 李亚伟, 翟书梅, 刘宏, 田俊芝. 老年2型糖尿病合并非酒精性脂肪肝血清 nesfatin-1变化及其影响因素[J]. 临床输血与检验, 2017, 19(2): 158-162.
[9]	潘爱平, 杨云霞, 徐洪磊. 2型糖尿病视网膜病变患者血清脂联素与VEGF水平的变化及意义[J]. 临床输血与检验, 2017, 19(2): 170-173.
[10]	王杰敏, 王杰彪, 梁满超. 早孕期糖化血红蛋白检测在妊娠期糖尿病诊断中的应用价值[J]. 临床输血与检验, 2016, 18(4): 376-377.